HCWB Latest Press Releases

-- November 5, 2026 --

HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing Globe Newswire 8:45 AM

-- October 9, 2026 --

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors Globe Newswire 9:00 AM

-- September 24, 2026 --

HCW Biologics Announces Pricing of $1.5 Million Private Placement Globe Newswire 8:25 AM

-- September 8, 2026 --

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells Globe Newswire 8:50 AM

-- September 2, 2026 --

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment Globe Newswire 9:00 AM

-- August 25, 2026 --

HCW Biologics' TGF- Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells Globe Newswire 9:00 AM

-- August 14, 2026 --

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Globe Newswire 3:15 PM

-- July 29, 2026 --

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering Globe Newswire 9:06 AM

-- July 23, 2026 --

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 Globe Newswire 8:00 AM

-- June 30, 2026 --

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter Globe Newswire 8:25 AM

-- June 26, 2026 --

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 Globe Newswire 8:55 AM

-- June 16, 2026 --

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes